Core Insights - The report highlights the significant role of CFOs in listed companies, with the total compensation for CFOs in A-share companies reaching 4.27 billion yuan in 2024 [1] CFO Demographics - The age distribution of CFOs shows that those aged 40-50 constitute 54% of the market, while CFOs over 50 account for 35%, and those under 40 make up 11% [1] - In terms of educational background, 71% of CFOs hold a bachelor's degree, 23% have a master's degree, and only 3% possess a doctoral degree, with only one CFO, Yan Hongyu from Yangpu Medical, holding a PhD [1] Compensation Analysis - The average annual salary for CFOs in A-share medical device companies is 1.0652 million yuan [1] - The distribution of salaries shows that 31% earn below 500,000 yuan, 43% earn between 500,000 and 1 million yuan, 20% earn between 1 million and 2 million yuan, and 6% earn above 2 million yuan [1] - The top three highest-paid CFOs are Zhao Yun from Mindray Medical at 8.4134 million yuan, Liu Lihua from Yuyue Medical at 4.3136 million yuan, and Jing Xiaokuan from Wandong Medical at 1.6412 million yuan [1] Salary Changes - Among CFOs with over two years of tenure, Zhang Qiu from Kangtong Medical experienced the largest salary decrease of 31.23% year-on-year, while Xu Ning from Mcland saw the highest salary increase of 165.59% year-on-year [1]

Group 1 - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024, with an average annual salary of 814,800 yuan [1] - In the medical device sector, the average annual salary of CFOs is 1.0652 million yuan, with 31% earning below 500,000 yuan, 43% between 500,000 and 1 million yuan, 20% between 1 million and 2 million yuan, and 6% above 2 million yuan [2] - The age distribution of CFOs shows that 54% are aged between 40 and 50, 35% are over 50, and 11% are 40 or younger, with the youngest being 30 years old and the oldest being 65 years old [1] Group 2 - The top three highest-paid CFOs in the medical device sector are Zhao Yun from Mindray Medical with 8.4134 million yuan, Liu Lihua from Yuyue Medical with 4.3136 million yuan, and Jing Xiaoqian from Wandong Medical with 1.6412 million yuan [2] - The CFO with the largest salary decrease in 2024 is Zhang Qiu from Kangtong Medical, with a year-on-year decrease of 31.23%, while Xu Ning from Mcland saw the largest increase at 165.59% [2] - The educational background of CFOs shows that 71% hold a bachelor's degree, 23% a master's degree, and only 3% hold a doctoral degree, with only one CFO having a PhD [1]

每经AI快讯，Wind数据显示，8月7日，共有31只个股获券商买入评级，其中10只个股公布了目标价 格。按最高目标价计算，宁德时代、鱼跃医疗、徐工机械目标涨幅排名居前，涨幅分别达38.26%、 36.27%、33.1%。 （文章来源：每日经济新闻） ...

东方证券研报指出，鱼跃医疗家用医疗器械龙头，布局广阔。公司核心业务涵盖四大领域：呼吸制氧、 血糖及POCT、家用健康检测、临床器械及康复。公司新品布局围绕全球化、数字化和可穿戴化进行， 同时，公司积极研发AI智能穿戴医疗设备，基于公司在医疗领域的技术积累，将建设"监测-预警-干 预"全链条管线。2025年初，公司与Inogen签署《战略合作协议》。Inogen为一家美国呼吸制氧业务企 业，拥有广泛的欧美销售渠道，预计将与公司优势互补，实现协作共赢。公司业务现已逐步回归疫情后 的常态化、可持续发展轨道，作为国内家用医疗器械龙头，公司内生外延并举，产品线不断丰富，渠道 持续开拓，长期空间广阔。根据可比公司2025年平均估值，给予公司2025年24倍PE，对应目标价48.24 元，首次给予"买入"评级。 来源:金融界AI电报 ...

Core Viewpoint - Yuyue Medical is a leading player in the home medical device sector with a broad layout, focusing on four main areas: respiratory oxygen, blood glucose and POCT, home health monitoring (such as electronic blood pressure monitors), and clinical devices and rehabilitation [1] Group 1: Business Overview - The company's core business encompasses four major fields: respiratory oxygen, blood glucose and POCT, home health monitoring, and clinical devices and rehabilitation [1] - The company is actively developing AI smart wearable medical devices, leveraging its technological accumulation in the medical field to establish a comprehensive "monitoring-warning-intervention" pipeline [1] Group 2: Strategic Partnerships - In early 2025, the company signed a strategic cooperation agreement with Inogen, a US-based respiratory oxygen business with extensive sales channels in Europe and America, aiming for complementary advantages and collaborative win-win outcomes [1] Group 3: Market Position and Growth Potential - The company's business is gradually returning to a normalized and sustainable development track post-pandemic, positioning itself as a domestic leader in home medical devices [1] - The company is pursuing both organic growth and external expansion, continuously enriching its product line and expanding its channels, indicating significant long-term growth potential [1] Group 4: Valuation and Investment Rating - Based on comparable companies' average valuation for 2025, the company is assigned a 24 times PE ratio, corresponding to a target price of 48.24 yuan, with an initial "buy" rating [1]

Investment Rating - The report assigns a "Buy" rating for the company, with a target price of 48.24 CNY based on a 24x PE for 2025 [2][5]. Core Views - The company is positioned as a leader in the home medical device sector, with a diverse product line and a strong focus on both domestic and international markets. The business is expected to return to a sustainable growth trajectory post-pandemic, with significant long-term potential [2][9]. Financial Forecast and Investment Recommendations - The projected EPS for the company from 2025 to 2027 is 2.01, 2.36, and 2.78 CNY respectively. The revenue for 2025 is estimated at 8.669 billion CNY, reflecting a 14.6% year-on-year growth. The net profit attributable to the parent company is expected to be 2.011 billion CNY in 2025, with an 11.3% growth [2][4]. Company Overview - The company has a comprehensive product portfolio exceeding 600 types, focusing on four main areas: respiratory oxygen therapy, blood glucose and POCT, home health monitoring, and clinical devices and rehabilitation. It is also developing emergency response products [14][9]. Market Position and Growth Potential - The respiratory therapy segment is expected to generate 2.6 billion CNY in revenue for 2024, despite a 22.9% decline due to fluctuations in public demand. The blood glucose and POCT segment is projected to grow significantly, with a 40.2% increase in revenue to 1.03 billion CNY in 2024 [9][48]. Product Development and Innovation - The company is actively investing in R&D, focusing on global, digital, and wearable technologies. Key product innovations include continuous glucose monitoring (CGM) systems, which are expected to see substantial market growth, with the market size projected to reach 2.6 billion USD by 2030 [9][20]. Sales Channels and International Expansion - The company has established a comprehensive sales network that includes both online and offline channels, with online sales accounting for 38% of total sales in Q1 2025. The international business is also expanding rapidly, with overseas revenue expected to reach 0.95 billion CNY in 2024, a 30.4% increase [9][20].

风险提示：股市有风险，投资需谨慎。 鱼跃医疗8月6日股价报35.08元，较前一交易日下跌0.10元，跌幅0.28%。当日开盘价为35.17元，最高触 及35.30元，最低下探至34.97元，成交额2.76亿元，换手率0.84%。 来源:金融界 鱼跃医疗属于医疗器械行业，公司专注于医疗设备及耗材的研发、生产和销售，产品涵盖呼吸治疗、血 糖监测、康复护理等领域。 8月6日主力资金净流出3953.07万元，占流通市值的0.12%。近五个交易日累计净流出2094.17万元，占 流通市值的0.06%。 ...

7月31日，鱼跃医疗今日收盘34.88元，下跌1.77%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到19.74倍，总市值349.66亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均54.89倍，行业中值37.06倍，鱼跃医疗排 名第41位。 江苏鱼跃医疗设备股份有限公司的主营业务是研发、制造和销售医疗器械产品及提供相关解决方案。公 司产品主要集中在呼吸制氧、糖尿病护理、感染控制解决方案、家用类电子检测及体外诊断、急救与临 床及康复器械等业务领域。公司目前拥有"鱼跃yuwell"、"洁芙柔"、"华佗Hwato"、"金钟JZ"、"安尔 碘"、"普美康PRIMEDIC"、"六六视觉"等几大主要品牌。"鱼跃"品牌深入人心，依托鱼跃产品力的不断 提升及有效的品牌传播，以及旗下产品在海内外医疗一线的卓越表现，公司品牌价值和品牌优势显著提 升。 最新一期业绩显示，2025年一季报，公司实现营业收入24.36亿元，同比9.17%；净利润6.25亿元，同 比-5.26%，销售毛利率50.30%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)11鱼跃医疗19.7419.362.67349 ...

金融界消息 截至2025年7月31日收盘，鱼跃医疗（002223）报收于34.88元，下跌1.77%，换手率 1.46%，成交量13.77万手，成交金额4.83亿元。 来源：金融界 资金流向方面，今日主力资金净流入3097.90万元，占比成交额6.42%。其中，超大单净流出724.89万 元、占成交额1.5%，大单净流入3822.79万元、占成交额7.92%，中单净流出流出156.25万元、占成交额 0.32%，小单净流出2941.65万元、占成交额6.09%。 鱼跃医疗最新一期业绩显示，截至2025一季报，公司营业总收入24.36亿元、同比增长9.17%，归属净利 润6.25亿元，同比减少5.26%，扣非净利润5.13亿元，同比减少6.91%，流动比率3.426、速动比率 3.022、资产负债率19.43%。 天眼查商业履历信息显示，江苏鱼跃医疗设备股份有限公司，成立于1998年，位于镇江市，是一家以从 事专用设备制造业为主的企业。企业注册资本100247.6929万人民币，实缴资本100247.6929万人民币。 公司法定代表人为吴群。 通过天眼查大数据分析，江苏鱼跃医疗设备股份有限公司共对外投资了36家 ...

近日，证券之星第三届ESG新标杆企业评选结果揭晓，鱼跃医疗凭借在环境、社会和治理(ESG)领域的卓越实践，荣获"ESG新标杆企业奖"。该奖项是由证 券之星联合妙盈科技等专业权威机构，在中国首席经济学家论坛等指导下设立的ESG领域权威奖项，旨在挖掘并表彰在环境(如低碳减排、绿色供应链)、社 会(如乡村振兴、公益慈善)及公司治理(如合规管理、风险防控)三大维度实现卓越实践，推动经济效能与社会责任深度融合的企业。 在治理(G)层面，鱼跃医疗建立了结构清晰、权责分明的三层ESG管理体系(监督层、管理层、执行层)，并创新性地将ESG关键绩效纳入薪酬考核机制，确保 责任有效落实。公司严格遵循法规，完善的法人治理架构保障了运营透明度与合规性。董事会成员多元化成效显著，女性董事占比达44.4%，独立董事占据 多数，为科学决策提供了有力支撑。2024年，公司通过35次信息安全演练、100%覆盖的反腐培训(人均6.7小时)及严格的供应链验厂审核(覆盖30家供应商， 商业道德评估比100%)，筑牢了商业道德与信息安全的防线，全年未发生重大贪腐、不正当竞争或信息泄露事件。 在环境(E)责任方面，鱼跃医疗积极践行绿色运营理念。公司全年 ...